Revance Therapeutics, Inc. - Common Stock (RVNC)
3.6500
0.00 (0.00%)
Revance Therapeutics is a biotechnology company focused on developing innovative therapies for various medical conditions, primarily in the fields of aesthetics, neuromodulation, and pain management
The company specializes in creating advanced drug formulations and delivery technologies that aim to provide longer-lasting effects and improve patient outcomes. Through its proprietary products, Revance aims to address unmet medical needs while enhancing the quality of life for patients. The company's portfolio includes both aesthetic treatments and therapeutic applications, showcasing its commitment to innovation in the healthcare sector.

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Via Benzinga · January 17, 2025

Via Benzinga · December 9, 2024

Via Benzinga · November 12, 2024

Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%.
Via Benzinga · August 12, 2024

Via Benzinga · November 8, 2024

Via Benzinga · November 8, 2024

Via Benzinga · October 28, 2024

Via Benzinga · October 28, 2024

Revance Therapeutics stock is up on Monday as RVNC investors celebrate a $924 million merger agreement with Crown Laboratories.
Via InvestorPlace · August 12, 2024

Via Benzinga · August 12, 2024

RVNC stock results show that Revance Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024

The big pharma company's top drug is losing ground, but its dividend keeps rising.
Via The Motley Fool · July 22, 2024

Although breakout stocks present high risks, the underlying lack of predictability provides fuel for tremendous upside.
Via InvestorPlace · July 11, 2024

Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.
Via InvestorPlace · May 22, 2024

10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.
Via InvestorPlace · May 12, 2024

Via Benzinga · May 10, 2024

Via Benzinga · May 10, 2024

RVNC stock results show that Revance Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSEBB) rose sharply during Tuesday’s session.
Via Benzinga · April 9, 2024

U.S. stock futures were lower this morning, with the Dow futures falling by around 100 points on Monday. Shares of GDS Holdings Limited (NASDAQGDS) shares rose sharply in today’s pre-market trading.
Via Benzinga · March 11, 2024

Shares of Bitdeer Technologies Group (NASDAQBTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
Via Benzinga · March 4, 2024